within Pharmacolibrary.Drugs.ATC.N;

model N02AA03_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.9500000000000002e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0016899999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00117,
    k12             = 2.57,
    k21             = 2.57
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AA03_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Hydromorphone is a potent opioid analgesic used to relieve moderate to severe pain. It acts primarily as a mu-opioid receptor agonist and is approved for use in many countries. Hydromorphone is available in various formulations including oral, intravenous, and rectal preparations. It is commonly used in both acute and chronic pain management, particularly in hospital settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following intravenous bolus administration.</p><h4>References</h4><ol><li><p>Reed, R, et al., &amp; Giguère, S (2019). The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. <i>Veterinary anaesthesia and analgesia</i> 46(3) 395–404. DOI:<a href=&quot;https://doi.org/10.1016/j.vaa.2018.11.001&quot;>10.1016/j.vaa.2018.11.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30930095/&quot;>https://pubmed.ncbi.nlm.nih.gov/30930095</a></p></li><li><p>Nakatani, T, et al., &amp; Saito, Y (2023). Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain. <i>Journal of palliative medicine</i> 26(6) 768–775. DOI:<a href=&quot;https://doi.org/10.1089/jpm.2022.0289&quot;>10.1089/jpm.2022.0289</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36579915/&quot;>https://pubmed.ncbi.nlm.nih.gov/36579915</a></p></li><li><p>Wimbish, C, et al., &amp; Messenger, KM (2024). Pharmacokinetics of a continuous intravenous infusion of hydromorphone in healthy dogs. <i>Frontiers in veterinary science</i> 11 1362730–None. DOI:<a href=&quot;https://doi.org/10.3389/fvets.2024.1362730&quot;>10.3389/fvets.2024.1362730</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38686029/&quot;>https://pubmed.ncbi.nlm.nih.gov/38686029</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AA03_1;
